Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions
Condition(s) studied
Investigational drug(s) / intervention(s)
Drug-eluting stent implantation: IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups. In DES group, latest second-generation DES will be used in accordance with standard practice guideline.
Drug-coated balloon angioplasty: IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups. In DCB group, commercially available DCB (Agent, Boston Scientific, USA) will be used. DCB angioplasty will be recommended as follows to fully optimized procedural results. First, DCB size should be 1:1 ratio with reference vessel size. Second, delivery time of DCB should be within 30 seconds. Third, total inflation time of DCB will be recommended from 30 to 60 seconds.
Study summary
This study aims to compare late-lumen loss (LLL) between DCB and DES to treat de novo coronary artery stenosis by intravascular ultrasound (IVUS).
Eligibility
Primary outcome measure(s)
- Late-lumen loss — 9 months after last patient enrollment
Mean difference of late-lumen loss between DCB and DES in IVUS
Trial sites (8)
| Facility | City | Region | Status |
|---|---|---|---|
| Kosin University Gospel Hospital | Busan | South Korea | Not Yet Recruiting |
| Keimyung University Dongsan Hospital | Daegu | South Korea | Not Yet Recruiting |
| Chonnam National University | Gwangju | South Korea | Recruiting |
| Jeonbuk National University Hospital | Jeonju | South Korea | Not Yet Recruiting |
| Samsung Medical Center | Seoul | South Korea | Not Yet Recruiting |
| Ewha Womans University Mokdong Hospital | Seoul | South Korea | Not Yet Recruiting |
| Korea University Guro Hospital | Seoul | South Korea | Not Yet Recruiting |
| Ulsan University Hospital | Ulsan | South Korea | Not Yet Recruiting |
More Chonnam National University Hospital trials in South Korea
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06954714 on ClinicalTrials.gov ↗ ← All trials in South Korea